Biopharma deals boom as major players strike multiple $1B+ deals

Key findings

• PLS deal value surpassed $65B in the first quarter of 2026, marking the strongest quarter since 2020.

• 16 $1B+ biopharma deals were announced in the first quarter of 2026. Deal activity focused on differentiated science, GLP-1 expansion, and next-gen modalities including RNA, ADCs, and gene editing.

• Pricing headwinds from IRA, Most Favored Nation (MFN) ramifications, tariffs, and US-China trade policy uncertainty influenced negotiations but did not slow deal activity.

As we highlighted in our 2026 outlook, strategic dealmaking urgency has intensified. Large pharmaceutical players are accelerating their dealmaking and digging into their deep pockets to offset the estimated $300B+ of branded pharma revenue exposed to LOE this decade. Nearly every major player in the sector has announced at least one $1B+ biopharma deal in the last 12 months, with several completing multiple transactions. Focused and bespoke mid-cap biotech and bolt-on transactions remain the sweet spot for the biopharma M&A market as technological and scientific advances drive innovation, delivering differentiated patient outcomes faster than ever. We see the industry continuing to prefer smaller and more bespoke bets on science for the foreseeable future as it remains increasingly selective about larger M&A. AI’s growing ability to deliver efficiencies and synergies autonomously now rivals the benefits that large-scale M&A traditionally delivered. 

Beyond traditional biotech-pharma deal structures, US and European biopharmas are looking to China for truly innovative molecules across oncology, immunology, and metabolic disease. These broad discovery and development pacts are adding geopolitical complexity, while providing cutting-edge science at more favorable deal terms. AI-enabled R&D—both as an investment thesis and as a synergy lever within acquired pipelines and services platforms—is also moving from pitch deck narrative to core deal consideration.

Regulatory uncertainty remains a key concern for industry players. MFN drug pricing proposals, potential tariffs on pharmaceutical imports, and IRA negotiation expansions are all shaping transaction strategy. In response, buyers are relying more heavily on contingent value rights, milestone-based structures, and assets with near-term clinical or commercial inflection points rather than long-duration platform bets. In this environment, the pressure to maximize value from biotech deals requires a holistic and surgical approach.

At the same time, the buyer landscape is broadening across all PLS subsectors with private equity becoming more active. Several significant acquisitions across pharma and pharma services demonstrate how private equity and strategic buyers are increasingly competing for assets in the space. Carve-outs in life sciences services and tools are also creating new platforms in CDMO, CRO, and bioprocessing that could fuel additional bolt-on activity in the second half of 2026.

We expect two forces to shape the deals market over the next six months: greater urgency from pharma and tighter exits for biotech. First, large-cap pharma is likely to remain in active portfolio-replenishment mode. Deal activity continues to concentrate around high-growth, strong-margin therapeutic areas—cardiometabolic and obesity, immunology and inflammation, oncology, and rare disease—while radiopharmaceuticals and RNA medicines also continue to command a premium.

At the same time, while the biotech IPO window is slowly opening again, there are still only a small number of companies making their debut on the public market. IPOs are requiring increased proof of clinical success, making many biotechs seek alternative exits. Yet, those biotechs that have gone public are performing well so far. The favorable valuations are signaling renewed investor confidence and the influx of capital is helping fuel scientific advancement, while also pushing biotechs to progress further into clinical trials before seeking commercial partners. As a result, more advanced assets are driving higher deal values and volumes as large-cap buyers are willing to pay more for derisked assets that address looming LOE gaps. 

Moves dealmakers should be making now:

• Reassess your biotech integration playbook to ensure that deal logic appropriately translates to actual patient outcomes.

• Stress-test pipelines against MFN, IRA-expansion, and tariff scenarios before going to market.

• Prepare for more milestone-heavy and CVR-driven structures, particularly in highly competitive therapeutic areas.

• Scenario-plan AI-enabled R&D and SG&A synergies into deal models, as this is becoming a credibility test in management presentations across both biopharma and services.

• Private equity firms should strengthen relationships with large pharma now to capitalize on the growing carve-out pipeline across drug franchises and non-core services/tools.

With the biotech IPO window reopening, run dual-track processes to maximize value, as strategic buyers continue to pay premiums for the right asset.

Pharma and life sciences deal momentum is strong, broad, and set to continue into the second half of 2026. Large-cap pharma is targeting growth, while private equity seeks durability in specialty pharma and life sciences services. Capital and appetite are abundant. The scarce resource is differentiated assets with near-term commercial potential in the right therapeutic areas. Dealmakers that explicitly underwrite policy risk, embrace milestone-weighted deal structures, and bring AI-enabled insights to the table will be best positioned to lead this market. 

Explore national M&A trends